ZACKS
Search documents
Southern Co. (SO) Misses Q4 Earnings Estimates
ZACKS· 2026-02-19 14:40
Southern Co. (SO) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.5 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.79%. A quarter ago, it was expected that this power company would post earnings of $1.5 per share when it actually produced earnings of $1.6, delivering a surprise of +6.67%.Over the last four quarters, the company ha ...
Can Arista's High-Performance Network Software Fuel Its Future Growth?
ZACKS· 2026-02-19 14:36
Core Insights - Arista Networks, Inc. (ANET) is enhancing its market position with a software-driven networking platform utilizing its Extensible Operating System (EOS) and CloudVision, which provide scalability, automation, and visibility for modern, AI-ready networks [1] Group 1: Product and Technology - Arista's EOS is a Linux-based network operating system featuring a modular architecture and shared state database, allowing for fault isolation, in-service software upgrades, and consistent operations across its switching portfolio [2] - The CloudVision platform serves as a centralized network management and automation tool, offering unified automation, telemetry, and lifecycle management across various environments, along with AI-driven insights through Autonomous Virtual Assist [3] - New features in the EOS Smart AI Suite, such as Cluster Load Balancing and NetDL Streamer, are designed to enhance low-latency performance and telemetry, positioning Arista to capitalize on the growing demand for smarter networking solutions [4][8] Group 2: Competitive Landscape - Arista faces competition from Cisco Systems, which is focusing on AI-powered networking software and expanding its cloud platform for unified network management [5] - Hewlett Packard Enterprise (HPE) is also enhancing its networking software through its Aruba platform, emphasizing cloud-based management and AI insights [6] Group 3: Financial Performance and Valuation - Arista's shares have increased by 35% over the past year, contrasting with a 17% decline in the industry [7] - The company trades at a forward price-to-sales ratio of 15.98, significantly higher than the industry average of 3.86 [10] - Earnings estimates for 2026 have risen by 0.61% to $3.32, while estimates for 2027 have increased by 0.76% to $3.96 [11]
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
ZACKS· 2026-02-19 14:36
Key Takeaways BIO posted Q4 adjusted EPS of $2.51, missing estimates as shares sank 12.3%. BIO revenues rose 3.8% to $693.2M, led by Clinical Diagnostics growth of 8.4%. BIO guided 2026 currency-neutral revenue growth of 0.5-1.5% with 12-12.5% margin outlook.Bio-Rad Laboratories, Inc. (BIO) posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the prior-year quarter’s level.The quarter’s adjustments prim ...
Can Nebius Reach $7-$9B Annualized Run-Rate Revenue in 2026?
ZACKS· 2026-02-19 14:30
Key Takeaways Nebius targets $7B-$9B ARR by 2026, with 2026 revenue seen at $3B-$3.4B.Nebius topped $1.2B ARR in 2025, adding 9 data centers and over 2GW of contracted power.Nebius sees longer AI contracts, $4B pipeline growth and Microsoft revenue ramping in 2027.Nebius Group N.V. (NBIS) has outlined an ambitious yet clearly defined financial trajectory, targeting an annualized run rate (ARR) revenue of between $7 billion and $9 billion by the end of 2026. The company reiterated its confidence in achieving ...
Will Barrick Mining's Higher Costs Dent Its Profit Momentum Ahead?
ZACKS· 2026-02-19 14:30
Key Takeaways Barrick's Q4 profits rose on higher gold prices, but cash costs and AISC increased year over year.Lower production, partly from the Loulo-Gounkoto suspension, contributed to higher unit costs.Barrick's projected 2026 cash costs and AISC signal a year-over-year increase at the midpoint.Barrick Mining Corporation’s (B) fourth-quarter profits more than doubled year over year on higher gold prices, but steeper unit costs remained a drag. Its total cash costs per ounce of gold and all-in-sustainin ...
Endava PLC Sponsored ADR (DAVA) Matches Q2 Earnings Estimates
ZACKS· 2026-02-19 14:30
Endava PLC Sponsored ADR (DAVA) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.96%. A quarter ago, it was expected that this company would post earnings of $0.25 per share when it actually produced earnings of $0.2, delivering a surprise of -20%.Over the last four quarters, the company has sur ...
Progressive's January Earnings Increase Y/Y on Higher Premiums
ZACKS· 2026-02-19 14:25
Core Insights - The Progressive Corporation (PGR) reported earnings per share of $1.98 for January 2026, reflecting a 4% year-over-year increase driven by higher revenues and investment income, despite rising expenses [1][7] Financial Performance - Total revenues for Progressive reached $7.5 billion, marking a 5.3% increase year over year, attributed to a 5% rise in premiums and a 16% increase in investment income [3][7] - Net premiums written were $6.7 billion, up 4% from $6.5 billion in the same month last year, while net premiums earned rose 5% to approximately $6.9 billion [2] - The combined ratio deteriorated by 30 basis points year over year to 84.4, indicating a slight increase in claims and expenses relative to premiums [2] Policy Growth - Policies in force (PIF) in the Vehicle business increased significantly, with Personal Auto segment policies rising 10% to 37.6 million and Direct Auto policies improving 14% to 16.1 million [4] - The Property business also saw growth, with 3.6 million policies in force, up 3% year over year [5] Investment Metrics - The book value per share increased by 16.4% to $53.24 as of January 31, 2026, compared to $45.75 a year earlier [5] - The return on equity for the trailing 12 months was 38.9%, up 130 basis points from 37.6% in January 2025 [5] - The debt-to-total-capital ratio improved by 230 basis points year over year to 18.1 as of January 31, 2026 [5] Market Performance - Progressive shares have experienced a decline of 24.6% over the past year, contrasting with the industry's growth of 3.5% [6]
Appian (APPN) Surpasses Q4 Earnings and Revenue Estimates
ZACKS· 2026-02-19 14:25
Appian (APPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +59.57%. A quarter ago, it was expected that this business process management software provider would post earnings of $0.05 per share when it actually produced earnings of $0.32, delivering a surprise of +540%.Over the l ...
Bandwidth (BAND) Matches Q4 Earnings Estimates
ZACKS· 2026-02-19 14:25
分组1 - Bandwidth reported quarterly earnings of $0.35 per share, matching the Zacks Consensus Estimate, but down from $0.37 per share a year ago, resulting in an earnings surprise of -0.71% [1] - The company posted revenues of $207.67 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.24%, but down from $209.97 million year-over-year [2] - Bandwidth shares have declined approximately 15.9% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Bandwidth is uncertain, with current consensus EPS estimates at $0.34 for the coming quarter and $1.90 for the current fiscal year, with revenues expected to be $189.15 million and $840.33 million respectively [7] - The Communication - Infrastructure industry, to which Bandwidth belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
ZACKS· 2026-02-19 14:21
Core Insights - Exact Sciences Corporation (EXAS) reported a net loss of 21 cents per share in Q4 2025, which is higher than the loss of 6 cents in the same quarter last year, aligning with the Zacks Consensus Estimate [1] - For the full year 2025, earnings per share were 7 cents, a significant improvement from the loss of 23 cents in the previous year [1] EXAS Revenues - Q4 consolidated revenues reached $878.4 million, reflecting a 23.1% increase on a reported basis and 23% on a core revenue basis, surpassing the Zacks Consensus Estimate by 2.1% [2] - Full-year 2025 consolidated revenues totaled $3.25 billion, marking a 17.7% increase on a reported basis and 18% on a core revenue basis [2] - Following the earnings announcement, EXAS shares saw a slight increase of 0.07% [2] EXAS Q4 Segments in Detail - Screening revenues, which include laboratory service revenues from Cologuard and PreventionGenetics, amounted to $695.1 million, up 26% year over year [3] - Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183.2 million, reflecting a 14% year-over-year increase and 12% on a core basis [3] EXAS' Margins - Gross profit increased by 25% year over year to $615.8 million, with gross margin expanding by 106 basis points to 70.1% [4] - Research and development expenses rose by 96% year over year to $191.5 million, while sales and marketing expenses increased by 18% to $288.5 million [4] - General and administrative expenses grew by 14.1% year over year to $218 million [4] EXAS' Financial Update - At the end of Q4 2025, Exact Sciences had cash and cash equivalents and marketable securities totaling $964.7 million, down from $1.04 billion at the end of Q4 2024 [6] - Cumulative net cash provided by operating activities was $491.4 million, compared to $210.5 million in the previous year [6] Notable Developments - In Q4, Exact Sciences announced the first clinical study results from its Oncodetect molecular residual disease test in breast cancer, which showed favorable outcomes [10] - The company also reported pivotal clinical validation results from the ALTUS study during the quarter [10] - On November 19, 2025, Exact Sciences entered into a merger agreement with Abbott Laboratories, aiming for a close in Q2 2026, pending regulatory approvals [11]